Stage 2 clear cell renal cell carcinoma is typically curable, especially when detected early. Surgery remains the cornerstone ...
In a groundbreaking development for cancer treatment, Neomorph, a local biotech firm, has begun clinical trials for its innovative molecular glue, NEO-811. This nove ...
The first patient dosing in the Phase 1/2 trial represents a crucial step in assessing NEO-811's efficacy and safety. The Phase 1/2 NEO-811-101 trial is a first-in-human, open-label study designed to ...
TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit. During a presentation at the 2025 Kidney Cancer ...
The international CheckMate 025 phase III clinical trial recruited 821 patients with advanced clear cell kidney cancer, who had received prior treatment, between October 2012 and March 2014. They were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results